Tyrosine Kinase Inhibitors in the Treatment of Chronic-Phase CML: Strategies for Frontline Decision-making

[1] Arber DA(2016)The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia Blood 127 2391-2405

[2] Orazi A(1973)Letter: a new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining Nature 243 290-293

[3] Hasserjian R(1984)An alteration of the human c-abl protein in K562 leukemia cells unmasks associated tyrosine kinase activity Cell 37 1035-1042

[4] Thiele J(1998)Efficient and rapid induction of a chronic myelogenous leukemia-like myeloproliferative disease in mice receiving P210 bcr/abl-transduced bone marrow Blood 92 3780-3792

[5] Borowitz MJ(1999)The biology of chronic myeloid leukemia N Engl J Med 341 164-172

[6] Le Beau MM(1996)Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative Cancer Res 56 100-104

[7] Rowley JD(2002)Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and imatinib (STI-571) Cancer Res 62 4236-4243

[8] Konopka JB(2003)Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia N Engl J Med 348 994-1004

[9] Watanabe SM(2017)Long-term outcomes of imatinib treatment for chronic myeloid leukemia N Engl J Med 376 917-927

[10] Witte ON(2001)Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification Science 293 876-880

[1] Arber DA(2016)The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia Blood 127 2391-2405

[2] Orazi A(1973)Letter: a new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining Nature 243 290-293

[3] Hasserjian R(1984)An alteration of the human c-abl protein in K562 leukemia cells unmasks associated tyrosine kinase activity Cell 37 1035-1042

[4] Thiele J(1998)Efficient and rapid induction of a chronic myelogenous leukemia-like myeloproliferative disease in mice receiving P210 bcr/abl-transduced bone marrow Blood 92 3780-3792

[5] Borowitz MJ(1999)The biology of chronic myeloid leukemia N Engl J Med 341 164-172

[6] Le Beau MM(1996)Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative Cancer Res 56 100-104

[7] Rowley JD(2002)Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and imatinib (STI-571) Cancer Res 62 4236-4243

[8] Konopka JB(2003)Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia N Engl J Med 348 994-1004

[9] Watanabe SM(2017)Long-term outcomes of imatinib treatment for chronic myeloid leukemia N Engl J Med 376 917-927

[10] Witte ON(2001)Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification Science 293 876-880